Name | Benralizumab |
---|
Description | Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used to treat severe eosinophilic asthma[1]. |
---|---|
Related Catalog | |
Target |
IL-5Rα[1] |
References |
Molecular Formula | C6492H10060N1724O2028S42 |
---|---|
Molecular Weight | 146054.0 |